Genprex Granted FDA Orphan Drug Designation For REQORSA Immunogene Therapy For Treatment Of Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted Genprex an Orphan Drug Designation for its REQORSA immunogene therapy for the treatment of small cell lung cancer. This designation provides Genprex with certain benefits, including tax credits, market exclusivity for seven years, and exemption from certain FDA fees.
August 10, 2023 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's Orphan Drug Designation for Genprex's REQORSA could provide the company with significant benefits, potentially boosting its financial performance and stock price.
The Orphan Drug Designation provides Genprex with several benefits, including tax credits, market exclusivity for seven years, and exemption from certain FDA fees. These benefits could significantly improve the company's financial performance, potentially leading to a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100